...
首页> 外文期刊>American Journal of Ophthalmology: The International Journal of Ophthalmology >Comparison of Intravitreal Triamcinolone Acetonide With Photodynamic Therapy and Intravitreal Bevacizumab with Photodynamic Therapy for Retinal Angiomatous Proliferation
【24h】

Comparison of Intravitreal Triamcinolone Acetonide With Photodynamic Therapy and Intravitreal Bevacizumab with Photodynamic Therapy for Retinal Angiomatous Proliferation

机译:玻璃体腔注射曲安奈德与光动力疗法和玻璃体腔注射贝伐单抗与光动力疗法治疗视网膜血管瘤增生的比较

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: To compare the efficacy of combined therapy with intravitreal triamcinolone (IVTA) and photodynamic therapy (PDT; IVTA plus PDT) with intravitreal bevacizumab (IVB) and PDT (IVB plus PDT) for patients with retinal angiomatous proliferation (RAP). DESIGN: Retrospective, observational case series. METHODS: We retrospectively reviewed 25 treatment-naive eyes of 22 Japanese patients (11 men, 11 women) with retinal angiomatous proliferation. Twelve eyes of 11 patients were treated with combined therapy of IVTA plus PDT from September 1, 2004, through July 31,2006. Thirteen eyes of 11 patients were treated with combined therapy of IVB plus PDT from February 1,2007, through January 31, 2008.RESULTS: In 12 eyes treated with IVTA plus PDT, the mean best-corrected visual acuity (BCVA) levels at baseline and 12 months were 0.29 and 0.13, respectively. A significant (P < .05) decline in the mean BCVA from baseline was observed at 12 months. In 13 eyes treated with IVB plus PDT, the mean BCVA levels at baseline and 12 months were 0.25 and 0.37. A significant (P < .05) improvement in the mean BCVA from baseline was observed. At 12 months, the difference in BCVA between the 2 groups was significant (P < .05). The mean numbers of treatments at 12 months in the IVTA plus PDT group and the IVB plus PDT group were 2.7 and 1.6, respectively. The difference between the 2 treatments reached significance (P < .05). No complications developed.CONCLUSIONS: Compared with IVTA plus PDT, IVB plus PDT was significantly more effective in maintaining and improving visual acuity and in reducing the number of treatment for patients with retinal angiomatous proliferation.
机译:目的:比较玻璃体内注射曲安奈德(IVTA)和光动力疗法(PDT; IVTA加PDT)联合玻璃体内贝伐单抗(IVB)和PDT(IVB加PDT)联合治疗视网膜血管瘤增生(RAP)的疗效。设计:回顾性观察病例系列。方法:我们回顾性分析了22例日本人视网膜视网膜血管瘤增生的25例未经治疗的眼睛。从2004年9月1日至2006年7月31日,对11例患者的12眼进行了IVTA加PDT联合治疗。从2007年2月1日至2008年1月31日,对11例患者的13眼进行了IVB + PDT联合治疗。结果:在接受IVTA + PDT治疗的12眼中,基线时的平均最佳矫正视力(BCVA)水平和12个月分别为0.29和0.13。在12个月时观察到平均BCVA从基线显着下降(P <.05)。在用IVB + PDT治疗的13只眼中,基线和12个月时的平均BCVA水平为0.25和0.37。与基线相比,平均BCVA显着提高(P <.05)。在12个月时,两组之间的BCVA差异显着(P <.05)。 IVTA加PDT组和IVB加PDT组在12个月时的平均治疗次数分别为2.7和1.6。两种治疗之间的差异达到显着性(P <.05)。结论:与IVTA加PDT相比,IVB加PDT在维持和改善视敏度以及减少视网膜血管瘤增生患者的治疗次数方面更为有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号